Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.